Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
28. August 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Reports Second Quarter 2024 Financial Results
07. August 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces Leadership Updates
17. Juni 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
17. Juni 2024 06:00 ET
|
Keros Therapeutics, Inc.
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were...
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
04. Juni 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03. Juni 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
28. Mai 2024 16:01 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
14. Mai 2024 10:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
08. Mai 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
14. März 2024 08:00 ET
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...